|
Abnormal circle of Willis morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormality of brainstem morphology
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Amputated structure (morphologic abnormality)
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Besides, this study analyzed AGF levels in LEPAD patients according to disease severity and evaluated the prognostic value of AGF for amputation and mortality in LEPAD patients after a follow-up period of 1.7years.
|
27866700 |
2017 |
|
Aneurysm of aortic root
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
ANEURYSM, INTRACRANIAL BERRY, 1 (disorder)
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Rare Coding Variants in ANGPTL6 Are Associated with Familial Forms of Intracranial Aneurysm.
|
29304371 |
2018 |
|
Anorexia Nervosa
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ANGPTL6 levels of AN patients were increased relative to the control group (68.6 ± 9.9 ng/ml) and decreased from 110.2 ± 13.3 to 73.6 ± 7.1 ng/ml (p = 0.004) after partial realimentation.
|
27135654 |
2017 |
|
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Bladder Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
At IC50 for HAase activity inhibition (5-20 μg/ml [0.4-1.7 μM]), sHA-F significantly inhibited proliferation, motility and invasion of HYAL-1 expressing BCa cells (253J-Lung, HT1376, UMUC-3), P<0.001. sHA-F did not affect the growth of HYAL-1 non-expressing BCa (5637, RT4, T24, TCCSUP) and normal urothelial (Urotsa, SV-HUC1) cells. sHA-F treatment induced apoptosis by death receptor pathway. sHA-F downregulated transcript and/or protein levels of HA receptors (CD44, RHAMM), p-AKT, β-catenin, pβ-Catenin(S552), Snail and Twist but increased levels of pβ-Catenin(T41/S45), pGSK-3α/β(S21/S9) and E-cadherin. sHA-F also inhibited CD44/Phosphoinositide 3-kinase (PI-3K) complex formation and PI-3K activity.
|
27419371 |
2017 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
At IC50 for HAase activity inhibition (5-20 μg/ml [0.4-1.7 μM]), sHA-F significantly inhibited proliferation, motility and invasion of HYAL-1 expressing BCa cells (253J-Lung, HT1376, UMUC-3), P<0.001. sHA-F did not affect the growth of HYAL-1 non-expressing BCa (5637, RT4, T24, TCCSUP) and normal urothelial (Urotsa, SV-HUC1) cells. sHA-F treatment induced apoptosis by death receptor pathway. sHA-F downregulated transcript and/or protein levels of HA receptors (CD44, RHAMM), p-AKT, β-catenin, pβ-Catenin(S552), Snail and Twist but increased levels of pβ-Catenin(T41/S45), pGSK-3α/β(S21/S9) and E-cadherin. sHA-F also inhibited CD44/Phosphoinositide 3-kinase (PI-3K) complex formation and PI-3K activity.
|
27419371 |
2017 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identify angiopoietin-like 6 protein as a peptide-mimicked natural ligand enriched in hepatic blood vessels of CRC patients.
|
23070965 |
2012 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although the physiologic functions of human AGF have not yet been identified, serum levels of AGF displayed up-regulation in groups with diseases including preeclampsia and diabetes; and there was little association between genetic variability of AGF and metabolic syndrome-related phenotypes.
|
20673930 |
2011 |
|
Diabetes Mellitus
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Poor glycemic control in diabetes mellitus as reflected by higher serum HbA<sub>1c</sub> levels is associated with raised serum ANGPTL6 levels.
|
29033485 |
2018 |
|
Diabetes Mellitus
|
0.020 |
Biomarker
|
group |
BEFREE |
Although the physiologic functions of human AGF have not yet been identified, serum levels of AGF displayed up-regulation in groups with diseases including preeclampsia and diabetes; and there was little association between genetic variability of AGF and metabolic syndrome-related phenotypes.
|
20673930 |
2011 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to find whether long-term glycemic control (glycated hemoglobin [HbA<sub>1c</sub>]) has any correlation with serum ANGPTL6 levels in patients of type 2 diabetes mellitus.
|
29033485 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
VLCD decreased ANGPTL6 levels only in obese patients with T2DM.
|
27135654 |
2017 |
|
Dissection of aorta
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Encephalomalacia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Familial (FPAH)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Rare Coding Variants in ANGPTL6 Are Associated with Familial Forms of Intracranial Aneurysm.
|
29304371 |
2018 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Addition of exogenous miRNA-128 to CRL-1690 and CRL-2610 GBM cell lines (a) restored 'homeostatic' ARP5 (ANGPTL6), Bmi-1 and E2F-3a expression, and (b) significantly decreased the proliferation of CRL-1690 and CRL-2610 cell lines.
|
19941032 |
2010 |
|
Hemiparesis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Hypertensive disease
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
|
Hypertensive disease
|
0.110 |
Biomarker
|
group |
BEFREE |
We observed a higher rate of individuals with a history of high blood pressure among affected versus healthy individuals carrying ANGPTL6 variants, suggesting that ANGPTL6 could trigger cerebrovascular lesions when combined with other risk factors such as hypertension.
|
29304371 |
2018 |
|
Intermittent Claudication
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Among LEPAD patients, those with critical limb ischemia (n=43) showed higher AGF levels (124.9±73.9 vs. 88.98±53.26ng/mL, P=0.01) compared with those with intermittent claudication (n=62).
|
27866700 |
2017 |
|
Intracranial Aneurysm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Altogether, our results indicate that rare coding variants in ANGPTL6 are causally related to familial forms of IA.
|
29304371 |
2018 |
|
Limb ischemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Among LEPAD patients, those with critical limb ischemia (n=43) showed higher AGF levels (124.9±73.9 vs. 88.98±53.26ng/mL, P=0.01) compared with those with intermittent claudication (n=62).
|
27866700 |
2017 |